Lumatas Biosystems, Inc.

Lumatas Biosystems, Inc. specializes in developing analyte-specific reagent in vitro diagnostic (IVD) assays, which are designed to detect and measure specific biological markers in clinical samples. Their primary focus is on the goldFISH platform, a product line used for diagnostic testing purposes. These devices are intended for laboratory use to aid in medical diagnosis.

Lumatas Biosystems, Inc. is based in the United States. As a U.S.-based manufacturer, its devices are subject to FDA regulations, including registration in the FDA’s Unique Device Identifier (UDI) system. Additionally, since their products are marketed in the EU, they are also listed in EUDAMED, the European Union’s medical device registry, ensuring compliance with both U.S. and EU regulatory requirements.

Lumatas Biosystems, Inc.’s devices are listed in EUDAMED (the EU’s medical device registry) and the FDA’s UDI system (Unique Device Identifier database). These registries are critical because they ensure transparency in the medical device supply chain, facilitate traceability for regulatory authorities, and help healthcare providers verify the legitimacy and compliance status of the devices in use.

Lumatas Biosystems, Inc.’s devices are classified as Class A or Class I medical devices. This classification is typically assigned to low-risk devices, such as certain IVD assays, where the risk to patient safety is minimal. The classification determines the regulatory pathway and oversight required for market authorization, with Class A/Class I devices generally requiring less stringent pre-market review compared to higher-risk categories.

Healthcare providers may verify whether Lumatas Biosystems, Inc.’s devices are listed in EUDAMED or the FDA’s UDI system to confirm their legitimacy, ensure compliance with regulatory standards, and confirm that the devices meet necessary safety and performance requirements. This step helps prevent the use of counterfeit or unapproved devices, reducing risks in clinical settings.